{"gene":"CSNK2B","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":1994,"finding":"CKB2 (yeast ortholog of CSNK2B) encodes the 32-kDa regulatory beta'-subunit of casein kinase II in S. cerevisiae. The deduced sequence revealed a conserved cysteine-containing motif CPX3C-X22-CPXC, proposed as a novel metal-binding (zinc-binding) domain. Haploid cells harboring ckb2 null alleles are viable, demonstrating beta'-subunit is not essential on its own. Double disruption of CKB2 with either catalytic subunit gene (alpha or alpha') caused a synthetic growth phenotype (slow growth, flocculation), establishing that the beta'-subunit interacts physically and/or functionally with both catalytic subunits in vivo.","method":"Gene cloning, sequencing, null allele disruption, synthetic phenotype analysis in S. cerevisiae","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct genetic epistasis via double-mutant synthetic phenotype, sequence analysis defining conserved domain, replicated across multiple genetic backgrounds","pmids":["8027080"],"is_preprint":false},{"year":1996,"finding":"CSNK2B (casein kinase II beta subunit gene) was localized to a ~220-kb segment of the human MHC class III region on chromosome 6, mapped between the Hsp70 (HSPA1L) and BAT1 (D6S81E) genes, by genomic sequencing and cDNA isolation.","method":"Genomic DNA probing, cDNA isolation, exon trapping, Northern blot analysis","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by genomic and cDNA sequencing, single lab, multiple molecular methods","pmids":["8812450"],"is_preprint":false},{"year":2017,"finding":"De novo splice site variants in CSNK2B (c.175+2T>G; c.367+2T>C) produce abnormal, significantly reduced mRNA transcripts in patient fibroblasts, most likely generating truncated proteins, demonstrating that loss-of-function of the CK2β subunit causes intellectual disability and myoclonic epilepsy.","method":"Exome sequencing, mRNA expression analysis in patient fibroblasts (in silico and expression studies)","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct mRNA analysis in patient-derived cells confirming splice disruption, two independent patients with orthogonal in silico validation","pmids":["28585349"],"is_preprint":false},{"year":2018,"finding":"CSNK2B knockdown in neural stem cells promotes their proliferation and inhibits differentiation, and alters neuronal morphology and synaptic transmission, establishing a role for CSNK2B in neural stem cell fate and neuronal function.","method":"shRNA knockdown in neural stem cells; proliferation, differentiation, and synaptic transmission assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct knockdown with multiple cellular phenotypic readouts (proliferation, differentiation, morphology, synaptic transmission), single lab","pmids":["29483533"],"is_preprint":false},{"year":2020,"finding":"TNFAIP1 interacts with CSNK2B and promotes its ubiquitin-mediated proteasomal degradation via Cul3 E3 ligase, thereby attenuating CSNK2B-dependent NF-κB trans-activation in hepatocellular carcinoma cells. Enforced CSNK2B expression counteracts TNFAIP1-mediated suppression of HCC proliferation, migration, and angiogenesis.","method":"LC-MS/MS proteomics, Co-immunoprecipitation, Western blot, dual-luciferase reporter, immunofluorescence, in vitro and in vivo functional rescue experiments","journal":"EBioMedicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP validated by MS, functional rescue experiments in vitro and in vivo, multiple orthogonal methods (Co-IP, reporter assay, immunofluorescence, xenograft) in single study","pmids":["31901862"],"is_preprint":false},{"year":2021,"finding":"CSNK2B promotes colorectal cancer cell proliferation primarily by activating the mTOR signaling pathway, as demonstrated by knockdown/overexpression functional experiments and rescue assays using mTOR pathway modulators.","method":"Knockdown and overexpression in CRC cell lines, Western blot for mTOR pathway components, rescue experiments, in vivo tumorigenesis assay","journal":"Journal of cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss- and gain-of-function with rescue experiments confirming pathway, single lab","pmids":["33928514"],"is_preprint":false},{"year":2022,"finding":"De novo missense variants at Asp32 of CSNK2B (p.Asp32His, p.Asp32Asn) upregulate CSNK2B expression, impair interaction of CK2β with DVL3 and β-catenin, reduce phosphorylation of β-catenin by CK2, abolish active (nuclear) β-catenin, and globally dysregulate canonical Wnt signaling, causing a new intellectual disability-craniodigital syndrome distinct from POBINDS. Whole-phosphoproteome analysis confirmed absence of phosphorylation of 313 putative CK2 substrates enriched in Wnt/nuclear β-catenin regulation.","method":"Co-immunoprecipitation (DVL3, β-catenin with mutant CK2β), phospho-Western blot, immunofluorescence, whole-transcriptome and whole-phosphoproteome profiling of patient-derived lymphoblastoid cell lines","journal":"HGG advances","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (Co-IP, phosphoproteomics, transcriptomics, immunofluorescence) in patient-derived cells with variant-specific mechanistic follow-up","pmids":["35571680"],"is_preprint":false},{"year":2023,"finding":"CSNK2B (the regulatory subunit of CK2) directly interacts with IRF1 and constitutively enhances IRF1 binding to chromatin genome-wide, promoting transcription of antiviral genes such as PLAAT4. Depletion of CSNK2B causes aberrant accumulation of IRF1 at AFAP1 loci, downregulating AFAP1 transcription. CSNK2B also mediates phosphorylation-dependent activation of AFAP1-Src signaling and exerts suppressive effects against flaviviruses including dengue virus.","method":"Proteomics (IRF1 interactome), genome-wide CUT&RUN chromatin binding analysis, siRNA knockdown, antiviral assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — proteomics-identified interaction confirmed by genome-wide CUT&RUN chromatin binding, orthogonal functional knockdown assays, antiviral phenotype readout","pmids":["37094077"],"is_preprint":false},{"year":2023,"finding":"HIKER lncRNA modulates CSNK2B expression under hypoxia; downregulation of HIKER reduces CSNK2B, suppressing erythropoiesis. Upregulation of CSNK2B on a HIKER-knockdown background rescues erythropoiesis defects. Pharmacologic inhibition of CSNK2B drastically reduces erythroid colony formation, and CSNK2B knockdown in zebrafish causes a defect in hemoglobinization.","method":"RNA-Seq, lncRNA knockdown/overexpression, CSNK2B pharmacologic inhibition, zebrafish morpholino knockdown with hemoglobinization readout, rescue overexpression","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic rescue experiment (CSNK2B overexpression rescues HIKER KD phenotype), zebrafish KD with direct cellular phenotype, pharmacologic inhibition, single lab","pmids":["37022795"],"is_preprint":false},{"year":2023,"finding":"Loss of CK2β protein due to instability of mutant CSNK2B mRNA (p.Leu39Arg) and/or protein (p.Met132LeufsTer110) reduces the amount of CK2 holoenzyme complex and diminishes its kinase activity, establishing haploinsufficiency as the pathomechanism of POBINDS for these variants.","method":"In vitro mRNA/protein stability assays, kinase activity assay, structural/functional prediction combined with patient-derived cell in vitro experiments","journal":"Genes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct measurement of CK2 complex abundance and kinase activity in patient-derived cells, two variant types assessed, single lab","pmids":["36833176"],"is_preprint":false},{"year":2024,"finding":"RACK1 interacts with CSNK2B (CK2β), inhibiting its ubiquitination and degradation. This stabilization allows CK2 to activate the NF-κB pathway, increasing CDK4 and cyclin D3 transcription and driving G2/M cell cycle progression in meningioma cells. The RACK1 inhibitor harringtonolide suppresses this pathway.","method":"Protein co-immunoprecipitation, mass spectrometry, RNA interference, transcriptome sequencing, in vivo xenograft experiments","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP validated by MS, pathway analysis by transcriptomics, in vivo experiments, single lab","pmids":["38398158"],"is_preprint":false},{"year":2025,"finding":"Pathogenic missense variants in the zinc-finger domain of CSNK2B (p.Arg111Pro, p.Cys137Phe) reduce CK2β protein stability via proteasomal and lysosomal degradation, alter CK2β subcellular localization, and significantly reduce CK2β homodimerization; CK2α binding is not affected. In contrast, variants p.Asp32Asn and p.Arg86Cys do not affect stability or CK2β/α binding, suggesting their pathological mechanism depends on altered protein-protein interactions with external factors.","method":"In vitro protein stability assays with proteasomal/lysosomal inhibitors, subcellular localization imaging, co-immunoprecipitation for homodimerization and CK2α binding","journal":"Biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal in vitro methods (stability assays, localization, Co-IP for two distinct interactions), four variants tested, mechanistic dissection of distinct classes of mutation","pmids":["40317201"],"is_preprint":false},{"year":2025,"finding":"AAV-PHP.eB-mediated neonatal brain-wide CSNK2B gene replacement in Csnk2b haploinsufficient mice restores cortical/hippocampal structure, normalizes neuronal numbers and PV-interneuron density, prolongs survival, rescues spontaneous seizures and ASD-like social/cognitive behaviors, and corrects EEG signatures (theta/gamma power, interregional coherence, gamma-band directional connectivity), demonstrating that reduced Csnk2b dosage disrupts cortical development and network synchronization and can be corrected post-natally.","method":"Csnk2b+/- mouse generation, AAV gene replacement (hsyn and CAG promoters), behavioral assays, in vivo EEG, histology, immunofluorescence for PV interneurons","journal":"bioRxiv (preprint) / Cell reports. Medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo mouse model with full rescue by gene replacement across multiple orthogonal readouts (behavior, EEG, histology, survival); corroborated by both preprint and peer-reviewed publication","pmids":["42190665"],"is_preprint":false},{"year":2013,"finding":"CSNK2B and the downstream gene LY6G5B form chimeric transcripts (Csnk2b-Ly6g5b) conserved across six mammalian species in multiple tissues. Overexpressed CSNK2B, LY6G5B, and chimeric CSNK2B-LY6G5B proteins show different patterns of post-translational modifications and distinct cell distribution, suggesting altered C-terminus of CSNK2B (from chimeric transcripts) could affect substrate specificity.","method":"RT-PCR across tissues and species, protein overexpression with post-translational modification profiling and subcellular localization analysis","journal":"BMC genomics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, overexpression-based localization and PTM observation without direct functional consequence established for the chimeric protein","pmids":["23521802"],"is_preprint":false}],"current_model":"CSNK2B encodes CK2β, the regulatory subunit of the heterotetrameric serine/threonine kinase CK2; CK2β homodimerizes (via a zinc-finger domain essential for stability) and binds CK2α catalytic subunits to form the holoenzyme, whose activity is required for normal neural development, cortical circuit formation, and inhibitory interneuron density. CK2β directly interacts with IRF1 to enhance chromatin binding and antiviral gene transcription, engages the canonical Wnt pathway (phosphorylating β-catenin via DVL3/β-catenin interactions), activates mTOR and NF-κB signaling, and is subject to ubiquitin-mediated proteasomal degradation regulated by TNFAIP1/Cul3 and stabilized by RACK1; haploinsufficiency or zinc-finger domain missense variants reduce holoenzyme abundance and kinase activity, causing neurodevelopmental disorder (POBINDS), while gain-of-function Asp32 variants dominantly perturb Wnt signaling to produce a distinct craniodigital syndrome."},"narrative":{"mechanistic_narrative":"CSNK2B encodes CK2β, the regulatory subunit of the protein kinase CK2, which assembles with catalytic α subunits into an active holoenzyme; genetic epistasis in yeast first established that the β subunit is dispensable for viability on its own yet interacts physically and functionally with both catalytic subunits, and harbors a conserved cysteine-rich zinc-binding motif [PMID:8027080]. This zinc-finger domain mediates CK2β homodimerization and protein stability: pathogenic missense variants within it (p.Arg111Pro, p.Cys137Phe) destabilize CK2β through proteasomal and lysosomal degradation and reduce homodimerization without affecting CK2α binding, while other variants act through altered external protein interactions rather than stability [PMID:40317201]. CK2β abundance is set by competing post-translational controls — TNFAIP1 recruits the Cul3 E3 ligase to drive ubiquitin-mediated proteasomal degradation [PMID:31901862], whereas RACK1 binding inhibits CK2β ubiquitination and stabilizes the protein [PMID:38398158]. Through the holoenzyme, CK2β engages multiple signaling outputs: it activates NF-κB to drive CDK4/cyclin D3 transcription and cell-cycle progression [PMID:38398158], activates mTOR signaling to promote proliferation [PMID:33928514], and supports canonical Wnt signaling by interacting with DVL3 and β-catenin to enable CK2-mediated β-catenin phosphorylation and nuclear β-catenin activity [PMID:35571680]. CK2β also directly binds the transcription factor IRF1, enhancing its genome-wide chromatin binding and antiviral gene transcription [PMID:37094077]. At the organismal level, reduced CK2β dosage disrupts neural stem cell fate, neuronal morphology, and synaptic transmission [PMID:29483533], and brain-wide gene replacement in haploinsufficient mice restores cortical structure, PV-interneuron density, network synchronization, and behavior [PMID:42190665]. Haploinsufficiency from loss-of-function variants that reduce holoenzyme abundance and kinase activity causes the neurodevelopmental disorder POBINDS [PMID:28585349, PMID:36833176], whereas dominant Asp32 variants that perturb Wnt signaling produce a distinct intellectual disability-craniodigital syndrome [PMID:35571680].","teleology":[{"year":1994,"claim":"Established that the CK2 β subunit is a non-essential regulatory partner that physically and/or functionally interacts with both catalytic subunits, and defined its conserved cysteine-rich zinc-binding motif.","evidence":"Gene cloning, sequencing, and double-mutant synthetic phenotype analysis of the yeast ortholog CKB2 in S. cerevisiae","pmids":["8027080"],"confidence":"High","gaps":["Did not establish the structural role of the zinc-binding motif in the holoenzyme","Functional interaction inferred from genetics, not biochemically resolved"]},{"year":1996,"claim":"Localized human CSNK2B to the MHC class III region of chromosome 6, providing the genomic context for the gene.","evidence":"Genomic DNA probing, cDNA isolation, exon trapping, and Northern blot in human","pmids":["8812450"],"confidence":"Medium","gaps":["No functional consequence of the chromosomal location established","No regulatory elements characterized"]},{"year":2013,"claim":"Identified conserved chimeric CSNK2B-LY6G5B transcripts whose altered CK2β C-terminus might affect substrate specificity, raising the possibility of isoform diversity.","evidence":"RT-PCR across tissues and species with overexpression-based PTM and localization profiling","pmids":["23521802"],"confidence":"Low","gaps":["Overexpression-based observation without functional consequence demonstrated for the chimeric protein","Substrate-specificity hypothesis untested","Endogenous abundance and physiological role unknown"]},{"year":2017,"claim":"Linked CSNK2B loss-of-function to human disease, showing splice variants produce reduced/abnormal transcripts and cause intellectual disability with myoclonic epilepsy (POBINDS).","evidence":"Exome sequencing and patient-fibroblast mRNA expression analysis","pmids":["28585349"],"confidence":"Medium","gaps":["Truncated proteins inferred but not directly demonstrated","Did not quantify holoenzyme abundance or kinase activity"]},{"year":2018,"claim":"Demonstrated a cellular role in the nervous system, with CSNK2B controlling neural stem cell proliferation/differentiation and neuronal morphology and synaptic transmission.","evidence":"shRNA knockdown in neural stem cells with proliferation, differentiation, and synaptic readouts","pmids":["29483533"],"confidence":"Medium","gaps":["Downstream molecular effectors not defined","Single lab, knockdown only"]},{"year":2020,"claim":"Defined a degradation control on CK2β abundance, showing TNFAIP1 recruits Cul3 to ubiquitinate and degrade CSNK2B, attenuating its NF-κB trans-activation.","evidence":"LC-MS/MS, reciprocal Co-IP, luciferase reporter, and in vitro/in vivo rescue in hepatocellular carcinoma cells","pmids":["31901862"],"confidence":"High","gaps":["Ubiquitination sites on CK2β not mapped","Link between CK2β and NF-κB activation mechanistically incomplete"]},{"year":2021,"claim":"Connected CSNK2B to mTOR signaling as a driver of colorectal cancer proliferation.","evidence":"Knockdown/overexpression with mTOR-modulator rescue and in vivo tumorigenesis in CRC cells","pmids":["33928514"],"confidence":"Medium","gaps":["Mechanism of mTOR activation by CK2β not resolved","Direct substrates not identified"]},{"year":2022,"claim":"Revealed a distinct gain-of-function disease mechanism, where Asp32 variants impair CK2β-DVL3/β-catenin interaction and β-catenin phosphorylation, dysregulating canonical Wnt signaling to cause a craniodigital syndrome.","evidence":"Co-IP, phospho-Western, immunofluorescence, transcriptomics and whole-phosphoproteomics in patient-derived lymphoblastoid cells","pmids":["35571680"],"confidence":"High","gaps":["Why Asp32 variants upregulate CSNK2B expression unexplained","Genotype-phenotype distinction from POBINDS not fully mechanistically separated"]},{"year":2023,"claim":"Established a direct transcriptional/antiviral role, showing CK2β binds IRF1 and constitutively enhances its genome-wide chromatin binding to control antiviral and AFAP1-Src gene programs and suppress flaviviruses.","evidence":"IRF1 interactome proteomics, genome-wide CUT&RUN, siRNA knockdown, and antiviral assays","pmids":["37094077"],"confidence":"High","gaps":["Whether enhancement of IRF1 chromatin binding requires CK2 kinase activity not resolved","Holoenzyme dependence of the IRF1 interaction unclear"]},{"year":2023,"claim":"Implicated CSNK2B in erythropoiesis, with HIKER lncRNA regulating CK2β levels and CK2β required for hemoglobinization and erythroid colony formation.","evidence":"RNA-Seq, lncRNA knockdown/overexpression rescue, pharmacologic CK2β inhibition, and zebrafish morpholino knockdown","pmids":["37022795"],"confidence":"Medium","gaps":["Direct erythroid substrates/effectors not defined","How HIKER regulates CSNK2B mechanistically unclear"]},{"year":2023,"claim":"Demonstrated haploinsufficiency as the POBINDS pathomechanism for specific variants by showing reduced CK2 holoenzyme abundance and kinase activity from mRNA/protein instability.","evidence":"In vitro mRNA/protein stability and kinase activity assays in patient-derived cells (p.Leu39Arg, p.Met132LeufsTer110)","pmids":["36833176"],"confidence":"Medium","gaps":["Single lab; two variants only","Downstream substrate-level consequences not measured"]},{"year":2024,"claim":"Identified a stabilizing control on CK2β, showing RACK1 binding inhibits CK2β ubiquitination/degradation to sustain NF-κB-driven cell-cycle gene expression in meningioma.","evidence":"Co-IP, mass spectrometry, RNAi, transcriptomics, and xenograft experiments","pmids":["38398158"],"confidence":"Medium","gaps":["RACK1 binding site on CK2β not mapped","Competition between RACK1 and TNFAIP1/Cul3 not directly tested"]},{"year":2025,"claim":"Resolved distinct molecular consequences of zinc-finger versus other pathogenic variants, showing zinc-finger variants destabilize CK2β and impair homodimerization while sparing CK2α binding, whereas Asp32Asn/Arg86Cys act through altered external interactions.","evidence":"In vitro stability assays with proteasomal/lysosomal inhibitors, localization imaging, and Co-IP for homodimerization and CK2α binding across four variants","pmids":["40317201"],"confidence":"High","gaps":["External interaction partners altered by Asp32Asn/Arg86Cys not identified here","Kinase-activity consequences of altered localization not quantified"]},{"year":2025,"claim":"Provided causal in vivo proof that reduced Csnk2b dosage disrupts cortical development and network synchronization and is correctable postnatally by gene replacement.","evidence":"Csnk2b+/- mice with AAV-PHP.eB brain-wide gene replacement, behavior, in vivo EEG, and histology","pmids":["42190665"],"confidence":"High","gaps":["Molecular pathway linking CK2β dosage to PV-interneuron density not defined","Therapeutic window and durability beyond model not addressed"]},{"year":null,"claim":"How CK2β's multiple downstream outputs (Wnt, NF-κB, mTOR, IRF1) are coordinated and which depend on holoenzyme kinase activity versus kinase-independent scaffolding remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model distinguishing kinase-dependent from scaffolding functions","Substrate map across tissues incomplete","Mechanism connecting CK2β dosage to specific neurodevelopmental endpoints unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,9,11]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[6,9]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[7]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6,7]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,6,10]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[10]}],"complexes":["CK2 holoenzyme"],"partners":["CSNK2A1","TNFAIP1","CUL3","RACK1","IRF1","DVL3","CTNNB1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P67870","full_name":"Casein kinase II subunit beta","aliases":["Phosvitin","Protein G5a"],"length_aa":215,"mass_kda":24.9,"function":"Regulatory subunit of casein kinase II/CK2. As part of the kinase complex regulates the basal catalytic activity of the alpha subunit a constitutively active serine/threonine-protein kinase that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine (PubMed:11239457, PubMed:16818610). Participates in Wnt signaling (By similarity) (Microbial infection) Upon infection with Epstein-Barr virus (EBV), the interaction with viral EBNA1 increases the association of CK2 with PML proteins, which increases PML phosphorylation by CK2, triggering the polyubiquitylation and degradation of PML (PubMed:20719947, PubMed:24216761). Seems to also suppress EBV reactivation by mediating ARK2N and JUN at the Z promoter which inhibits BZLF1 transcrition (PubMed:31341047)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P67870/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/CSNK2B","classification":"Common Essential","n_dependent_lines":1148,"n_total_lines":1208,"dependency_fraction":0.9503311258278145},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000204435","cell_line_id":"CID001052","localizations":[{"compartment":"nuclear_punctae","grade":3},{"compartment":"nucleoplasm","grade":3},{"compartment":"membrane","grade":2}],"interactors":[{"gene":"CSNK2A1","stoichiometry":10.0},{"gene":"CSNK2A2","stoichiometry":10.0},{"gene":"CSNK2A1;CSNK2A3","stoichiometry":10.0},{"gene":"RPS6KA3","stoichiometry":10.0},{"gene":"SUB1","stoichiometry":4.0},{"gene":"DEK","stoichiometry":4.0},{"gene":"RNF2","stoichiometry":4.0},{"gene":"SSRP1","stoichiometry":4.0},{"gene":"TOP2A","stoichiometry":4.0},{"gene":"CAPZB","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001052","total_profiled":1310},"omim":[{"mim_id":"620525","title":"LONG INTERGENIC NONCODING RNA 2228; LINC02228","url":"https://www.omim.org/entry/620525"},{"mim_id":"619818","title":"ELONGATION FACTOR 1; ELOF1","url":"https://www.omim.org/entry/619818"},{"mim_id":"618732","title":"POIRIER-BIENVENU NEURODEVELOPMENTAL SYNDROME; POBINDS","url":"https://www.omim.org/entry/618732"},{"mim_id":"616182","title":"CHRONIC MOUNTAIN SICKNESS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/616182"},{"mim_id":"611731","title":"APC REGULATOR OF WNT SIGNALING PATHWAY; APC","url":"https://www.omim.org/entry/611731"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli fibrillar center","reliability":"Additional"},{"location":"Perinuclear theca","reliability":"Additional"},{"location":"Calyx","reliability":"Additional"},{"location":"Mid piece","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CSNK2B"},"hgnc":{"alias_symbol":["Ckb1","Ckb2"],"prev_symbol":[]},"alphafold":{"accession":"P67870","domains":[{"cath_id":"2.20.25.20","chopping":"8-173","consensus_level":"medium","plddt":95.819,"start":8,"end":173}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P67870","model_url":"https://alphafold.ebi.ac.uk/files/AF-P67870-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P67870-F1-predicted_aligned_error_v6.png","plddt_mean":93.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CSNK2B","jax_strain_url":"https://www.jax.org/strain/search?query=CSNK2B"},"sequence":{"accession":"P67870","fasta_url":"https://rest.uniprot.org/uniprotkb/P67870.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P67870/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P67870"}},"corpus_meta":[{"pmid":"29483533","id":"PMC_29483533","title":"Comprehensive integrative analyses identify GLT8D1 and CSNK2B as schizophrenia risk genes.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29483533","citation_count":88,"is_preprint":false},{"pmid":"30655572","id":"PMC_30655572","title":"Identification of de novo CSNK2A1 and CSNK2B variants in cases of global developmental delay with seizures.","date":"2019","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30655572","citation_count":64,"is_preprint":false},{"pmid":"28585349","id":"PMC_28585349","title":"CSNK2B splice site mutations in patients cause intellectual disability with or without myoclonic epilepsy.","date":"2017","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/28585349","citation_count":56,"is_preprint":false},{"pmid":"8027080","id":"PMC_8027080","title":"Cloning and disruption of CKB2, the gene encoding the 32-kDa regulatory beta'-subunit of Saccharomyces cerevisiae casein kinase II.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8027080","citation_count":45,"is_preprint":false},{"pmid":"31901862","id":"PMC_31901862","title":"Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.","date":"2020","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/31901862","citation_count":36,"is_preprint":false},{"pmid":"31784560","id":"PMC_31784560","title":"Germline de novo variants in CSNK2B in Chinese patients with epilepsy.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31784560","citation_count":31,"is_preprint":false},{"pmid":"31781497","id":"PMC_31781497","title":"Huaier Suppresses Breast Cancer Progression via linc00339/miR-4656/CSNK2B Signaling Pathway.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31781497","citation_count":30,"is_preprint":false},{"pmid":"8812450","id":"PMC_8812450","title":"Localization of eight additional genes in the human major histocompatibility complex, including the gene encoding the casein kinase II beta subunit (CSNK2B).","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8812450","citation_count":26,"is_preprint":false},{"pmid":"34041744","id":"PMC_34041744","title":"CSNK2B: A broad spectrum of neurodevelopmental disability and epilepsy severity.","date":"2021","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/34041744","citation_count":25,"is_preprint":false},{"pmid":"35571680","id":"PMC_35571680","title":"De novo variants of CSNK2B cause a new intellectual disability-craniodigital syndrome by disrupting the canonical Wnt signaling pathway.","date":"2022","source":"HGG advances","url":"https://pubmed.ncbi.nlm.nih.gov/35571680","citation_count":21,"is_preprint":false},{"pmid":"33526068","id":"PMC_33526068","title":"Overexpression of NELFE contributes to gastric cancer progression via Wnt/β-catenin signaling-mediated activation of CSNK2B expression.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/33526068","citation_count":19,"is_preprint":false},{"pmid":"33166063","id":"PMC_33166063","title":"Poirier-Bienvenu neurodevelopmental syndrome: A report of a patient with a pathogenic variant in CSNK2B with abnormal linear growth.","date":"2020","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/33166063","citation_count":17,"is_preprint":false},{"pmid":"33928514","id":"PMC_33928514","title":"CSNK2B contributes to colorectal cancer cell proliferation by activating the mTOR signaling.","date":"2021","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/33928514","citation_count":15,"is_preprint":false},{"pmid":"36310603","id":"PMC_36310603","title":"Predictive functional, statistical and structural analysis of CSNK2A1 and CSNK2B variants linked to neurodevelopmental diseases.","date":"2022","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/36310603","citation_count":14,"is_preprint":false},{"pmid":"34370157","id":"PMC_34370157","title":"Clinical and genetic analysis of six Chinese children with Poirier-Bienvenu neurodevelopmental syndrome caused by CSNK2B mutation.","date":"2021","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/34370157","citation_count":14,"is_preprint":false},{"pmid":"37022795","id":"PMC_37022795","title":"Long noncoding RNA HIKER regulates erythropoiesis in Monge's disease via CSNK2B.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/37022795","citation_count":11,"is_preprint":false},{"pmid":"35370893","id":"PMC_35370893","title":"De Novo CSNK2B Mutations in Five Cases of Poirier-Bienvenu Neurodevelopmental Syndrome.","date":"2022","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35370893","citation_count":10,"is_preprint":false},{"pmid":"34983633","id":"PMC_34983633","title":"Two different presentations of de novo variants of CSNK2B: two case reports.","date":"2022","source":"Journal of medical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/34983633","citation_count":10,"is_preprint":false},{"pmid":"23521802","id":"PMC_23521802","title":"Intron retention and transcript chimerism conserved across mammals: Ly6g5b and Csnk2b-Ly6g5b as examples.","date":"2013","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/23521802","citation_count":7,"is_preprint":false},{"pmid":"35774559","id":"PMC_35774559","title":"Splicing Interruption by Intron Variants in CSNK2B Causes Poirier-Bienvenu Neurodevelopmental Syndrome: A Focus on Genotype-Phenotype Correlations.","date":"2022","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35774559","citation_count":7,"is_preprint":false},{"pmid":"36833176","id":"PMC_36833176","title":"Haploinsufficiency as a Foreground Pathomechanism of Poirer-Bienvenu Syndrome and Novel Insights Underlying the Phenotypic Continuum of CSNK2B-Associated Disorders.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36833176","citation_count":6,"is_preprint":false},{"pmid":"38398158","id":"PMC_38398158","title":"RACK1 Promotes Meningioma Progression by Activation of NF-κB Pathway via Preventing CSNK2B from Ubiquitination Degradation.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/38398158","citation_count":6,"is_preprint":false},{"pmid":"37094077","id":"PMC_37094077","title":"CSNK2B modulates IRF1 binding to functional DNA elements and promotes basal and agonist-induced antiviral signaling.","date":"2023","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/37094077","citation_count":5,"is_preprint":false},{"pmid":"39718697","id":"PMC_39718697","title":"Curzerenone inactivates the nuclear factor-kappa B signaling to suppress malignancy and immune evasion in cervical cancer by targeting CSNK2B.","date":"2024","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/39718697","citation_count":4,"is_preprint":false},{"pmid":"38037515","id":"PMC_38037515","title":"Genetic analysis and literature review of a Poirier-Bienvenu neurodevelopmental syndrome family line caused by a de novo frameshift variant in CSNK2B.","date":"2023","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38037515","citation_count":4,"is_preprint":false},{"pmid":"36617978","id":"PMC_36617978","title":"MicroRNA-1205 Suppresses Hepatocellular Carcinoma Cell Proliferation via a CSNK2B/CDK4 Axis.","date":"2023","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/36617978","citation_count":2,"is_preprint":false},{"pmid":"37717460","id":"PMC_37717460","title":"Refining of the electroclinical phenotype in familial and sporadic cases of CSNK2B-related Neurodevelopmental Syndrome.","date":"2023","source":"Epilepsy & behavior : E&B","url":"https://pubmed.ncbi.nlm.nih.gov/37717460","citation_count":2,"is_preprint":false},{"pmid":"39493709","id":"PMC_39493709","title":"Case report: Novel deletions in the 6p21.33 involving the CSNK2B gene in patients with Poirier-Bienvenu neurodevelopmental syndrome and literature review.","date":"2024","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39493709","citation_count":2,"is_preprint":false},{"pmid":"35598262","id":"PMC_35598262","title":"[De novo variant of CSNK2B causes Poirier-Bienvenu neurodevelopmental syndrome: two case report].","date":"2022","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35598262","citation_count":1,"is_preprint":false},{"pmid":"40317201","id":"PMC_40317201","title":"Pathogenic missense variants of CSNK2B associated with Poirier-Bienvenu neurodevelopmental disorder impact differently on CK2 holoenzyme formation.","date":"2025","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40317201","citation_count":0,"is_preprint":false},{"pmid":"39676320","id":"PMC_39676320","title":"CSNK2B Mutation: A Rare Cause of IGHD.","date":"2024","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/39676320","citation_count":0,"is_preprint":false},{"pmid":"40211296","id":"PMC_40211296","title":"Genetic analysis of four cases of Poirier Bienvenu neurodevelopmental syndrome associated with CSNK2B variant.","date":"2025","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/40211296","citation_count":0,"is_preprint":false},{"pmid":"42190665","id":"PMC_42190665","title":"CSNK2B gene replacement rescues autism-related phenotypes and establishes translational EEG biomarkers.","date":"2026","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/42190665","citation_count":0,"is_preprint":false},{"pmid":"41890472","id":"PMC_41890472","title":"Dravet Syndrome Associated With a CSNK2B-Related Neurodevelopmental Disorder.","date":"2026","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/41890472","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.23.684260","title":"AAV-mediated  <i>CSNK2B</i>  gene replacement rescues ASD-relevant phenotypes and establishes EEG biomarkers for translation in  <i>Csnk2b</i>  haploinsufficient mice","date":"2025-10-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.23.684260","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":19254,"output_tokens":4020,"usd":0.059031,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11941,"output_tokens":4515,"usd":0.08629,"stage2_stop_reason":"end_turn"},"total_usd":0.145321,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"CKB2 (yeast ortholog of CSNK2B) encodes the 32-kDa regulatory beta'-subunit of casein kinase II in S. cerevisiae. The deduced sequence revealed a conserved cysteine-containing motif CPX3C-X22-CPXC, proposed as a novel metal-binding (zinc-binding) domain. Haploid cells harboring ckb2 null alleles are viable, demonstrating beta'-subunit is not essential on its own. Double disruption of CKB2 with either catalytic subunit gene (alpha or alpha') caused a synthetic growth phenotype (slow growth, flocculation), establishing that the beta'-subunit interacts physically and/or functionally with both catalytic subunits in vivo.\",\n      \"method\": \"Gene cloning, sequencing, null allele disruption, synthetic phenotype analysis in S. cerevisiae\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct genetic epistasis via double-mutant synthetic phenotype, sequence analysis defining conserved domain, replicated across multiple genetic backgrounds\",\n      \"pmids\": [\"8027080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CSNK2B (casein kinase II beta subunit gene) was localized to a ~220-kb segment of the human MHC class III region on chromosome 6, mapped between the Hsp70 (HSPA1L) and BAT1 (D6S81E) genes, by genomic sequencing and cDNA isolation.\",\n      \"method\": \"Genomic DNA probing, cDNA isolation, exon trapping, Northern blot analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by genomic and cDNA sequencing, single lab, multiple molecular methods\",\n      \"pmids\": [\"8812450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"De novo splice site variants in CSNK2B (c.175+2T>G; c.367+2T>C) produce abnormal, significantly reduced mRNA transcripts in patient fibroblasts, most likely generating truncated proteins, demonstrating that loss-of-function of the CK2β subunit causes intellectual disability and myoclonic epilepsy.\",\n      \"method\": \"Exome sequencing, mRNA expression analysis in patient fibroblasts (in silico and expression studies)\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct mRNA analysis in patient-derived cells confirming splice disruption, two independent patients with orthogonal in silico validation\",\n      \"pmids\": [\"28585349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CSNK2B knockdown in neural stem cells promotes their proliferation and inhibits differentiation, and alters neuronal morphology and synaptic transmission, establishing a role for CSNK2B in neural stem cell fate and neuronal function.\",\n      \"method\": \"shRNA knockdown in neural stem cells; proliferation, differentiation, and synaptic transmission assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct knockdown with multiple cellular phenotypic readouts (proliferation, differentiation, morphology, synaptic transmission), single lab\",\n      \"pmids\": [\"29483533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TNFAIP1 interacts with CSNK2B and promotes its ubiquitin-mediated proteasomal degradation via Cul3 E3 ligase, thereby attenuating CSNK2B-dependent NF-κB trans-activation in hepatocellular carcinoma cells. Enforced CSNK2B expression counteracts TNFAIP1-mediated suppression of HCC proliferation, migration, and angiogenesis.\",\n      \"method\": \"LC-MS/MS proteomics, Co-immunoprecipitation, Western blot, dual-luciferase reporter, immunofluorescence, in vitro and in vivo functional rescue experiments\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP validated by MS, functional rescue experiments in vitro and in vivo, multiple orthogonal methods (Co-IP, reporter assay, immunofluorescence, xenograft) in single study\",\n      \"pmids\": [\"31901862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CSNK2B promotes colorectal cancer cell proliferation primarily by activating the mTOR signaling pathway, as demonstrated by knockdown/overexpression functional experiments and rescue assays using mTOR pathway modulators.\",\n      \"method\": \"Knockdown and overexpression in CRC cell lines, Western blot for mTOR pathway components, rescue experiments, in vivo tumorigenesis assay\",\n      \"journal\": \"Journal of cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss- and gain-of-function with rescue experiments confirming pathway, single lab\",\n      \"pmids\": [\"33928514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"De novo missense variants at Asp32 of CSNK2B (p.Asp32His, p.Asp32Asn) upregulate CSNK2B expression, impair interaction of CK2β with DVL3 and β-catenin, reduce phosphorylation of β-catenin by CK2, abolish active (nuclear) β-catenin, and globally dysregulate canonical Wnt signaling, causing a new intellectual disability-craniodigital syndrome distinct from POBINDS. Whole-phosphoproteome analysis confirmed absence of phosphorylation of 313 putative CK2 substrates enriched in Wnt/nuclear β-catenin regulation.\",\n      \"method\": \"Co-immunoprecipitation (DVL3, β-catenin with mutant CK2β), phospho-Western blot, immunofluorescence, whole-transcriptome and whole-phosphoproteome profiling of patient-derived lymphoblastoid cell lines\",\n      \"journal\": \"HGG advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (Co-IP, phosphoproteomics, transcriptomics, immunofluorescence) in patient-derived cells with variant-specific mechanistic follow-up\",\n      \"pmids\": [\"35571680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CSNK2B (the regulatory subunit of CK2) directly interacts with IRF1 and constitutively enhances IRF1 binding to chromatin genome-wide, promoting transcription of antiviral genes such as PLAAT4. Depletion of CSNK2B causes aberrant accumulation of IRF1 at AFAP1 loci, downregulating AFAP1 transcription. CSNK2B also mediates phosphorylation-dependent activation of AFAP1-Src signaling and exerts suppressive effects against flaviviruses including dengue virus.\",\n      \"method\": \"Proteomics (IRF1 interactome), genome-wide CUT&RUN chromatin binding analysis, siRNA knockdown, antiviral assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — proteomics-identified interaction confirmed by genome-wide CUT&RUN chromatin binding, orthogonal functional knockdown assays, antiviral phenotype readout\",\n      \"pmids\": [\"37094077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HIKER lncRNA modulates CSNK2B expression under hypoxia; downregulation of HIKER reduces CSNK2B, suppressing erythropoiesis. Upregulation of CSNK2B on a HIKER-knockdown background rescues erythropoiesis defects. Pharmacologic inhibition of CSNK2B drastically reduces erythroid colony formation, and CSNK2B knockdown in zebrafish causes a defect in hemoglobinization.\",\n      \"method\": \"RNA-Seq, lncRNA knockdown/overexpression, CSNK2B pharmacologic inhibition, zebrafish morpholino knockdown with hemoglobinization readout, rescue overexpression\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue experiment (CSNK2B overexpression rescues HIKER KD phenotype), zebrafish KD with direct cellular phenotype, pharmacologic inhibition, single lab\",\n      \"pmids\": [\"37022795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Loss of CK2β protein due to instability of mutant CSNK2B mRNA (p.Leu39Arg) and/or protein (p.Met132LeufsTer110) reduces the amount of CK2 holoenzyme complex and diminishes its kinase activity, establishing haploinsufficiency as the pathomechanism of POBINDS for these variants.\",\n      \"method\": \"In vitro mRNA/protein stability assays, kinase activity assay, structural/functional prediction combined with patient-derived cell in vitro experiments\",\n      \"journal\": \"Genes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct measurement of CK2 complex abundance and kinase activity in patient-derived cells, two variant types assessed, single lab\",\n      \"pmids\": [\"36833176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RACK1 interacts with CSNK2B (CK2β), inhibiting its ubiquitination and degradation. This stabilization allows CK2 to activate the NF-κB pathway, increasing CDK4 and cyclin D3 transcription and driving G2/M cell cycle progression in meningioma cells. The RACK1 inhibitor harringtonolide suppresses this pathway.\",\n      \"method\": \"Protein co-immunoprecipitation, mass spectrometry, RNA interference, transcriptome sequencing, in vivo xenograft experiments\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP validated by MS, pathway analysis by transcriptomics, in vivo experiments, single lab\",\n      \"pmids\": [\"38398158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Pathogenic missense variants in the zinc-finger domain of CSNK2B (p.Arg111Pro, p.Cys137Phe) reduce CK2β protein stability via proteasomal and lysosomal degradation, alter CK2β subcellular localization, and significantly reduce CK2β homodimerization; CK2α binding is not affected. In contrast, variants p.Asp32Asn and p.Arg86Cys do not affect stability or CK2β/α binding, suggesting their pathological mechanism depends on altered protein-protein interactions with external factors.\",\n      \"method\": \"In vitro protein stability assays with proteasomal/lysosomal inhibitors, subcellular localization imaging, co-immunoprecipitation for homodimerization and CK2α binding\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal in vitro methods (stability assays, localization, Co-IP for two distinct interactions), four variants tested, mechanistic dissection of distinct classes of mutation\",\n      \"pmids\": [\"40317201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"AAV-PHP.eB-mediated neonatal brain-wide CSNK2B gene replacement in Csnk2b haploinsufficient mice restores cortical/hippocampal structure, normalizes neuronal numbers and PV-interneuron density, prolongs survival, rescues spontaneous seizures and ASD-like social/cognitive behaviors, and corrects EEG signatures (theta/gamma power, interregional coherence, gamma-band directional connectivity), demonstrating that reduced Csnk2b dosage disrupts cortical development and network synchronization and can be corrected post-natally.\",\n      \"method\": \"Csnk2b+/- mouse generation, AAV gene replacement (hsyn and CAG promoters), behavioral assays, in vivo EEG, histology, immunofluorescence for PV interneurons\",\n      \"journal\": \"bioRxiv (preprint) / Cell reports. Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo mouse model with full rescue by gene replacement across multiple orthogonal readouts (behavior, EEG, histology, survival); corroborated by both preprint and peer-reviewed publication\",\n      \"pmids\": [\"42190665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CSNK2B and the downstream gene LY6G5B form chimeric transcripts (Csnk2b-Ly6g5b) conserved across six mammalian species in multiple tissues. Overexpressed CSNK2B, LY6G5B, and chimeric CSNK2B-LY6G5B proteins show different patterns of post-translational modifications and distinct cell distribution, suggesting altered C-terminus of CSNK2B (from chimeric transcripts) could affect substrate specificity.\",\n      \"method\": \"RT-PCR across tissues and species, protein overexpression with post-translational modification profiling and subcellular localization analysis\",\n      \"journal\": \"BMC genomics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, overexpression-based localization and PTM observation without direct functional consequence established for the chimeric protein\",\n      \"pmids\": [\"23521802\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CSNK2B encodes CK2β, the regulatory subunit of the heterotetrameric serine/threonine kinase CK2; CK2β homodimerizes (via a zinc-finger domain essential for stability) and binds CK2α catalytic subunits to form the holoenzyme, whose activity is required for normal neural development, cortical circuit formation, and inhibitory interneuron density. CK2β directly interacts with IRF1 to enhance chromatin binding and antiviral gene transcription, engages the canonical Wnt pathway (phosphorylating β-catenin via DVL3/β-catenin interactions), activates mTOR and NF-κB signaling, and is subject to ubiquitin-mediated proteasomal degradation regulated by TNFAIP1/Cul3 and stabilized by RACK1; haploinsufficiency or zinc-finger domain missense variants reduce holoenzyme abundance and kinase activity, causing neurodevelopmental disorder (POBINDS), while gain-of-function Asp32 variants dominantly perturb Wnt signaling to produce a distinct craniodigital syndrome.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CSNK2B encodes CK2β, the regulatory subunit of the protein kinase CK2, which assembles with catalytic α subunits into an active holoenzyme; genetic epistasis in yeast first established that the β subunit is dispensable for viability on its own yet interacts physically and functionally with both catalytic subunits, and harbors a conserved cysteine-rich zinc-binding motif [#0]. This zinc-finger domain mediates CK2β homodimerization and protein stability: pathogenic missense variants within it (p.Arg111Pro, p.Cys137Phe) destabilize CK2β through proteasomal and lysosomal degradation and reduce homodimerization without affecting CK2α binding, while other variants act through altered external protein interactions rather than stability [#11]. CK2β abundance is set by competing post-translational controls — TNFAIP1 recruits the Cul3 E3 ligase to drive ubiquitin-mediated proteasomal degradation [#4], whereas RACK1 binding inhibits CK2β ubiquitination and stabilizes the protein [#10]. Through the holoenzyme, CK2β engages multiple signaling outputs: it activates NF-κB to drive CDK4/cyclin D3 transcription and cell-cycle progression [#10], activates mTOR signaling to promote proliferation [#5], and supports canonical Wnt signaling by interacting with DVL3 and β-catenin to enable CK2-mediated β-catenin phosphorylation and nuclear β-catenin activity [#6]. CK2β also directly binds the transcription factor IRF1, enhancing its genome-wide chromatin binding and antiviral gene transcription [#7]. At the organismal level, reduced CK2β dosage disrupts neural stem cell fate, neuronal morphology, and synaptic transmission [#3], and brain-wide gene replacement in haploinsufficient mice restores cortical structure, PV-interneuron density, network synchronization, and behavior [#12]. Haploinsufficiency from loss-of-function variants that reduce holoenzyme abundance and kinase activity causes the neurodevelopmental disorder POBINDS [#2, #9], whereas dominant Asp32 variants that perturb Wnt signaling produce a distinct intellectual disability-craniodigital syndrome [#6].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established that the CK2 β subunit is a non-essential regulatory partner that physically and/or functionally interacts with both catalytic subunits, and defined its conserved cysteine-rich zinc-binding motif.\",\n      \"evidence\": \"Gene cloning, sequencing, and double-mutant synthetic phenotype analysis of the yeast ortholog CKB2 in S. cerevisiae\",\n      \"pmids\": [\"8027080\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the structural role of the zinc-binding motif in the holoenzyme\", \"Functional interaction inferred from genetics, not biochemically resolved\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Localized human CSNK2B to the MHC class III region of chromosome 6, providing the genomic context for the gene.\",\n      \"evidence\": \"Genomic DNA probing, cDNA isolation, exon trapping, and Northern blot in human\",\n      \"pmids\": [\"8812450\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional consequence of the chromosomal location established\", \"No regulatory elements characterized\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified conserved chimeric CSNK2B-LY6G5B transcripts whose altered CK2β C-terminus might affect substrate specificity, raising the possibility of isoform diversity.\",\n      \"evidence\": \"RT-PCR across tissues and species with overexpression-based PTM and localization profiling\",\n      \"pmids\": [\"23521802\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Overexpression-based observation without functional consequence demonstrated for the chimeric protein\", \"Substrate-specificity hypothesis untested\", \"Endogenous abundance and physiological role unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked CSNK2B loss-of-function to human disease, showing splice variants produce reduced/abnormal transcripts and cause intellectual disability with myoclonic epilepsy (POBINDS).\",\n      \"evidence\": \"Exome sequencing and patient-fibroblast mRNA expression analysis\",\n      \"pmids\": [\"28585349\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Truncated proteins inferred but not directly demonstrated\", \"Did not quantify holoenzyme abundance or kinase activity\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated a cellular role in the nervous system, with CSNK2B controlling neural stem cell proliferation/differentiation and neuronal morphology and synaptic transmission.\",\n      \"evidence\": \"shRNA knockdown in neural stem cells with proliferation, differentiation, and synaptic readouts\",\n      \"pmids\": [\"29483533\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream molecular effectors not defined\", \"Single lab, knockdown only\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a degradation control on CK2β abundance, showing TNFAIP1 recruits Cul3 to ubiquitinate and degrade CSNK2B, attenuating its NF-κB trans-activation.\",\n      \"evidence\": \"LC-MS/MS, reciprocal Co-IP, luciferase reporter, and in vitro/in vivo rescue in hepatocellular carcinoma cells\",\n      \"pmids\": [\"31901862\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitination sites on CK2β not mapped\", \"Link between CK2β and NF-κB activation mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected CSNK2B to mTOR signaling as a driver of colorectal cancer proliferation.\",\n      \"evidence\": \"Knockdown/overexpression with mTOR-modulator rescue and in vivo tumorigenesis in CRC cells\",\n      \"pmids\": [\"33928514\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of mTOR activation by CK2β not resolved\", \"Direct substrates not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a distinct gain-of-function disease mechanism, where Asp32 variants impair CK2β-DVL3/β-catenin interaction and β-catenin phosphorylation, dysregulating canonical Wnt signaling to cause a craniodigital syndrome.\",\n      \"evidence\": \"Co-IP, phospho-Western, immunofluorescence, transcriptomics and whole-phosphoproteomics in patient-derived lymphoblastoid cells\",\n      \"pmids\": [\"35571680\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why Asp32 variants upregulate CSNK2B expression unexplained\", \"Genotype-phenotype distinction from POBINDS not fully mechanistically separated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established a direct transcriptional/antiviral role, showing CK2β binds IRF1 and constitutively enhances its genome-wide chromatin binding to control antiviral and AFAP1-Src gene programs and suppress flaviviruses.\",\n      \"evidence\": \"IRF1 interactome proteomics, genome-wide CUT&RUN, siRNA knockdown, and antiviral assays\",\n      \"pmids\": [\"37094077\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether enhancement of IRF1 chromatin binding requires CK2 kinase activity not resolved\", \"Holoenzyme dependence of the IRF1 interaction unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Implicated CSNK2B in erythropoiesis, with HIKER lncRNA regulating CK2β levels and CK2β required for hemoglobinization and erythroid colony formation.\",\n      \"evidence\": \"RNA-Seq, lncRNA knockdown/overexpression rescue, pharmacologic CK2β inhibition, and zebrafish morpholino knockdown\",\n      \"pmids\": [\"37022795\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct erythroid substrates/effectors not defined\", \"How HIKER regulates CSNK2B mechanistically unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated haploinsufficiency as the POBINDS pathomechanism for specific variants by showing reduced CK2 holoenzyme abundance and kinase activity from mRNA/protein instability.\",\n      \"evidence\": \"In vitro mRNA/protein stability and kinase activity assays in patient-derived cells (p.Leu39Arg, p.Met132LeufsTer110)\",\n      \"pmids\": [\"36833176\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; two variants only\", \"Downstream substrate-level consequences not measured\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified a stabilizing control on CK2β, showing RACK1 binding inhibits CK2β ubiquitination/degradation to sustain NF-κB-driven cell-cycle gene expression in meningioma.\",\n      \"evidence\": \"Co-IP, mass spectrometry, RNAi, transcriptomics, and xenograft experiments\",\n      \"pmids\": [\"38398158\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RACK1 binding site on CK2β not mapped\", \"Competition between RACK1 and TNFAIP1/Cul3 not directly tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Resolved distinct molecular consequences of zinc-finger versus other pathogenic variants, showing zinc-finger variants destabilize CK2β and impair homodimerization while sparing CK2α binding, whereas Asp32Asn/Arg86Cys act through altered external interactions.\",\n      \"evidence\": \"In vitro stability assays with proteasomal/lysosomal inhibitors, localization imaging, and Co-IP for homodimerization and CK2α binding across four variants\",\n      \"pmids\": [\"40317201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"External interaction partners altered by Asp32Asn/Arg86Cys not identified here\", \"Kinase-activity consequences of altered localization not quantified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Provided causal in vivo proof that reduced Csnk2b dosage disrupts cortical development and network synchronization and is correctable postnatally by gene replacement.\",\n      \"evidence\": \"Csnk2b+/- mice with AAV-PHP.eB brain-wide gene replacement, behavior, in vivo EEG, and histology\",\n      \"pmids\": [\"42190665\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular pathway linking CK2β dosage to PV-interneuron density not defined\", \"Therapeutic window and durability beyond model not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CK2β's multiple downstream outputs (Wnt, NF-κB, mTOR, IRF1) are coordinated and which depend on holoenzyme kinase activity versus kinase-independent scaffolding remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model distinguishing kinase-dependent from scaffolding functions\", \"Substrate map across tissues incomplete\", \"Mechanism connecting CK2β dosage to specific neurodevelopmental endpoints unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 9, 11]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [6, 9]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 6, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"complexes\": [\"CK2 holoenzyme\"],\n    \"partners\": [\"CSNK2A1\", \"TNFAIP1\", \"CUL3\", \"RACK1\", \"IRF1\", \"DVL3\", \"CTNNB1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}